Cervical cancer, often caused by persistent human papillomavirus (HPV) infections, remains a public health challenge worldwide despite falling diagnoses related to the success of the HPV vaccine[GR1] in young adult women.
A new study published April 4 in Cancer Cell was led by Yale Cancer Center researchers, who collaborated with investigators nationally to differentiate the molecular subgroups of RCC tumors to better understand how their makeup might affect treatment responses.
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
Yale Cancer Center (YCC) and Smilow Cancer Hospital physicians and scientists will share new data for breakthrough and emerging cancer treatments as well as new discoveries in obesity, tobacco, evolution, and early onset cancers in early April at the American Association for Cancer Research (AACR) annual meeting.
Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).
One major hurdle in the development of safe and effective immunotherapies has been the risk of depleting healthy T cells during CAR-T treatment that seeks out and kills cancerous T-cells. In a new study published in Nature Communications, Yale Cancer Center researchers have developed a novel CAR-T cell therapy designed to efficiently kill cancerous T cells while leaving most healthy cells intact.
Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium as well as the ASCO Genitourinary Cancers Symposium this month.
A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with advanced-stage disease is needed.
The targeted therapy trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate, is now an approved treatment of HER2-low advanced breast cancers. In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with allotransplantation.
Two antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), were approved by the FDA to treat metastatic breast cancers. ADCs are a type of targeted therapy that release cancer drugs to specific tumor cells. The efficacy of T-DXd and SG depends on target expression and the best method for measuring that expression is still not known.
Based on the results from this phase III trial, Yale Cancer Center expert Dr. Amer Zeidan says imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower risk MDS patients.
Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9. The international symposium provides leading-edge breast cancer information on prevention, etiology, diagnosis, and therapy as well as experimental biology. This year’s symposium, at the Henry B.
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12. This year’s ASH meeting will include oral and poster presentations, workshops, and educational sessions for hematology professionals.
Using nanoparticles administered directly into the cerebrospinal fluid (CSF), a research team has developed a treatment that may overcome significant challenges in treating a particularly deadly brain cancer.
Yale Cancer Center researchers at Yale School of Medicine will present new cancer research at the European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, October 20 to 24. The annual meeting brings together clinicians, researchers, and patient advocates from all over the world. At ESMO 2023, oncologists will discuss new data and report updates on ongoing studies.
A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus (HPV) protein does not depend on its amino acid sequence or composition.
Cancer-related fatigue (CRF) is a debilitating yet all-too-common condition, which can severely affect quality of life for patients undergoing treatment. For those struggling with CRF, there have been no effective pharmaceutical treatments for the constellation of symptoms that together define the syndrome.
Yale Cancer Center physicians, scientists, and trainees from Yale School of Medicine present new findings at the 65th annual American Society for Radiation Oncology (ASTRO) meeting from October 1-4 in San Diego, Calif.
What are some of the biggest challenges you face in caring for cancers in children? The biggest challenges are around supporting the parents. For the most part, children are resilient and upbeat.
Colon cancers that spread to the liver may be substantially different depending on the location of where cancerous cells originate, according to new research. The study led by Yale Cancer Center researchers at Yale School of Medicine and Yale School of Public Health provides insight into the unique biology of right-sided and left-sided tumors, which may impact treatment options and patient outcomes.
What advances have made the biggest impact in the treatment of patients with thyroid cancer over the last five years, and what is the outlook for thyroid cancer in the next five years? Molecular testing (MT) to examine somatic changes has become an important adjunct in the diagnosis and treatment of many cancers.
Prostate screening is a critical part of early diagnosis. How would you encourage a man reading this to see his doctor to begin prostate screenings? The decision to screen for prostate cancer is highly individualized, considering each man’s personal risk, race, as well as other potential health conditions.
As we honor lymphoma awareness month, what do you want our patients and families to pause and remember?Lymphoma is a disease which can strike any one of us, young and old, at any time.
Treatment planning for lung cancer can often be complex due to variations in assessing immune biomarkers. In a new study, Yale Cancer Center researchers at Yale School of Medicine used artificial intelligence (AI) tools and digital pathology to improve the accuracy of this process.
Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance.
A new Yale Cancer Center study finds a targeted diet and exercise intervention could improve outcomes for women undergoing chemotherapy for breast cancer.
The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Penile squamous cell carcinoma is a rare form of penile cancer with limited treatment options. An international study led by Yale Cancer Center researchers at Yale School of Medicine finds that the use of immune checkpoint inhibitors (ICIs) offers promising clinical benefits for some patients with advanced penile squamous cell carcinoma.
Breast cancer screening for women over 70 is not without risks, according to new research from Yale School of Medicine’s COPPER Center. Although some guidelines recommend continuing screening for older women, a new study emphasizes the importance of assessing potential harms associated with testing, such as overdiagnosis, which, researchers say, can negatively affect quality of life.
One common side effect of treatment for ovarian cancer is chemotherapy-induced peripheral neuropathy (CIPN), which can damage peripheral nerves, causing severe pain and numbness. The effects can last for months – or even years — after completing chemotherapy. Currently, there is only one treatment with limited efficacy for CIPN.
Targeted therapies have revolutionized cancer treatment and the field of oncology. The FDA has approved over 70 targeted therapies for various cancer types, including lung cancer. Epidermal growth factor receptor (EGFR) mutations are found in a significant proportion of lung adenocarcinomas, and the use of tyrosine kinase inhibitors (TKIs) such as osimertinib, have improved patient outcomes.
Smilow Cancer Hospital at Yale New Haven is ranked as one of the highest hospitals for cancer care in the country by U.S. News & World Report. This year, Smilow Cancer Hospital at Yale New Haven is listed in the top 50 in the nation and is number 1 in Connecticut. "We are proud to be recognized as one of the leading cancer hospitals in our country,” said Eric Winer, MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital.
Human papillomavirus (HPV) has been linked to a significant increase in cancers of the throat and tonsils over the past few decades; this is projected to become the most common form of head and neck cancer by 2030. But a major limitation to reducing treatment intensity is the inability to correctly identify the patients whose HPV-related cancers will be the most responsive to treatment.
Immune-checkpoint inhibitors have become the standard of care for patients with advanced melanoma to improve survival, but only some patients respond to this immunotherapy and have long-term benefits. The lack of a long-lasting response, researchers say, is related to failure of antitumor immunologic memory. Treatment options for advanced melanoma are limited for patients who do not respond to this type of therapy.
Chimeric antigen receptor (CAR)-T cells are a powerful, new form of cancer therapy that are being studied to treat blood cancers. Using a new approach, Yale Cancer Center researchers at Yale School of Medicine found a new way to substantially improve the effectiveness of CAR-T cell therapy. The new study was published in Nature Immunology on July 27.
While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.
Cancer cells with extra chromosomes depend on those chromosomes for tumor growth, a new Yale study reveals, and eliminating them prevents the cells from forming tumors. The findings, said the researchers, suggest that selectively targeting extra chromosomes may offer a new route for treating cancer. The study was published July 6 in the journal Science.
Low-risk branch duct intraductal papillary mucinous neoplasms (IPMN) are the most common precancerous form of mucinous pancreatic cysts and once identified require regular surveillance imaging. But consensus is still forming around how long that watchful period should last.
Cancer immunotherapy has revolutionized treatment of many forms of cancer by unleashing the immune system response against tumors. Immunotherapies that block checkpoint receptors like PD-1, proteins that limit the capacity of T cells to attack tumors, have become the choice for the treatment of numerous types of solid cancer.
Healthy human skin is a mosaic-like collection of both normal and mutation-bearing cells. As people age, a growing number of these cells accumulate more and more mutations including those that can cause cancer. Eventually these mutant cells, which are fueled by environmental insults such as high sun exposure, gradually outcompete the healthy cells, making individuals increasingly susceptible to skin cancers.
By their early 20s, two of Yale’s most prominent cancer experts had each been immersed in healthcare battles for many years. Few people would have been surprised if they chose careers outside of healthcare. Instead, Drs. Eric Winer and Patricia LoRusso chose to pursue cancer care and research as their work. Both are now leaders of two of the country’s most prestigious organizations for cancer professionals.
A new study led by Yale Cancer Center shows improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer taking osimertinib (TAGRISSO), a targeted therapy, following surgery. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, tends to recur when diagnosed at advanced stages, which makes treatment challenging.
In response to the opioid epidemic in the United States, interventions to prevent over-prescribing and misuse of opioids were enacted at institutional, state, and federal levels. To assess how changes in the prescribing landscape affected patients, a research team from the Yale COPPER Center examined the rates of both new and persistent opioid prescribing in patients with cancer as well as in patients without cancer, utilizing data from SEER-Medicare.
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.
For families facing the end of life of a loved one with pediatric cancer, robust quality measures to benchmark what parents value most in their child’s medical care do not currently exist. A new study helps identify what parents prioritize for their children with advanced cancer, including alleviating the child’s symptoms and honoring the family’s goals and wishes.